

MEDIA RELEASE

Positive Industry Interest in LNP-LANFA Demonstrated at BIO International Convention 2026

- **ABio following up with 37 pharmaceutical companies, biotechnology companies and research organisations, which could lead to licensing opportunities**

Singapore, 20 July 2026 – A Biotech Co., Limited (“ABio”), a subsidiary of SGX Mainboard-listed CDW Holding Limited (“CDW” or the “Group”), today announced the successful completion of its joint business development activities with Neoregen Biotech Co., Ltd. (“Neoregen”) at the BIO International Convention 2026 (“BIO USA”) held in San Diego, California, in June 2026.


BIO International Convention is one of the world’s largest partnering events for the biotechnology and pharmaceutical industries, providing a global platform for technology licensing, strategic collaborations and investment discussions.

During the convention, ABio presented its proprietary LANFA water-solubilisation platform, which was developed as a potential biocompatible and safer alternative to polyethylene glycol (“PEG”), as well as the new LNP-LANFA (Lipid Nanoparticle) platform jointly developed with Neoregen. Both technologies were presented to explore potential global licensing and research and development collaboration opportunities.

Strong Industry Interest in PEG Alternatives

Throughout BIO USA, ABio conducted **37 business meetings** with pharmaceutical companies, biotechnology companies and leading research organisations from multiple countries.

The discussions highlighted stronger-than-expected industry interest in alternatives to PEG, driven by growing concerns over PEG-associated immunogenicity and hypersensitivity.



ABio CEO, Mr. Yoshimi Koichi at BIO USA

LANFA, which is patented in Japan, is designed to improve water solubility of poorly water-soluble compounds through controlled hydroxyl-group chemistry while maintaining high biocompatibility. Based on discussions during the convention, pharmaceutical companies and research organisations expressed interest in further evaluating LANFA as a potential alternative formulation platform for selected functions currently served by PEG, including applications in next-generation drug delivery systems (“DDS”).

LANFA INTRODUCTION

LANFA is a water-solubility enhancement platform designed to make poorly water-soluble compounds and nanomedicines compatible with aqueous systems.

Patented in Japan

High Water Solubility

Biocompatible Design

DDS / LNP / Solid Formulation

01 Optimizes water solubility by controlling the number of hydroxyl (OH) groups.

02 Conjugates with hydrophobic compounds, enabling stable aqueous dispersion and formulation.

03 Engineered to support biocompatibility, stability, and application-specific functionality.


LANFA (Patented in Japan)

Progress Towards Potential Licensing Opportunities

During BIO USA, ABio and Neoregen presented the latest pre-clinical in vivo data from murine studies which demonstrated reduced liver accumulation and enhanced splenic distribution using the jointly developed LNP-LANFA platform. The results showed a 3.3-fold improvement in the spleen-to-liver distribution ratio. Enhanced splenic distribution is particularly valuable for vaccines and immune therapies, where delivery to immune cells is critical.

Following the convention, ABio will continue technical follow-up discussions with the 37 organisations, and will explore potential licensing and development collaborations with selected parties.

At this stage, no definitive licensing agreements have been entered into.



LNP-LANFA's in vivo murine test results showed strong potential to overcome the immunogenicity and hepatotoxicity challenges faced by PEG

Comment from Management

Mr Tomonori Kato, Chairman and CEO of CDW Holding Limited, said: *“BIO USA 2026 provided an important opportunity to introduce both the LANFA platform and our jointly developed LNP-LANFA technology to a broad range of pharmaceutical companies and research organisations. We were encouraged by the level of technical engagement and the interest expressed in evaluating alternatives to PEG for future drug delivery applications.*

The positive feedback received during the convention has resulted in ongoing discussions with selected organisations. We look forward to continuing these discussions as we seek potential licensing and collaboration opportunities for the technology.”

Early-Stage Discussions and Development

The discussions described above remain at an early stage. While the Group intends to pursue potential licensing and collaboration opportunities arising from BIO USA 2026, there can be no assurance that these discussions will result in definitive agreements or future commercial revenues. The LNP-LANFA technology remains in the pre-clinical stage of development, and further non-clinical studies, regulatory review and clinical development will be required before any commercial application.

- End -

About CDW Holding Limited

(www.cdw-holding.com.hk)

CDW Holding Limited (the “Company”, and together with its subsidiaries, the “Group”) is a Japanese-managed precision components specialist serving the global market focusing on the production and supply of niche precision components for digital instrument panels in the automobile industry, notebook computers, consumer and information technology equipment, office equipment and electrical appliances, and an original equipment manufacturer. The Group is headquartered in Hong Kong and has operations in Japan, China, South Korea, Thailand and the Philippines. Since 2016, the Company has been identifying new businesses with growth potential to invest in, and as part of its diversification strategy, has made forays into the Life Sciences sector. The Company’s aim for its Life Sciences business is to identify research-driven yet commercialisable projects that can have a positive impact on the quality of human life.

Issued on behalf of	:	CDW Holding Limited
By	:	The Cogent Group
Contact	:	Karina Choo / Gerald Woon
Office	:	(65) 6704 9288
Email / DID / Mobile	:	karina@cogentcomms.com / (65) 6704 9280 / (65) 9107 6991 woon@cogentcomms.com / (65) 6704 9268 / (65) 9694 8364